Infliximab, CAS 170277-31-3

Product Description: Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research[1][2].

Applications: Metabolism-sugar/lipid metabolism

Formula: N/A

References: [1]Lucia A Méndez-García, et al. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88(5):e12716./[2]Isamu Yamakawa, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52.

CAS Number: 170277-31-3

Molecular Weight: N/A

Compound Purity: 90.30

Research Area: Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cancer

Solubility: H2O : 100 mg/mL (ultrasonic)

Target: Bacterial;TNF Receptor

• Artikelnummer: MEXHY-P9970-25
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9970-25
• Verpackungseinheit: 25 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated